Biotricity, Inc. (BTCY) Q2 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong revenue growth, improved profitability, and strategic market expansion. While there are risks, such as regulatory hurdles and market penetration challenges, the company's positive free cash flows, improved gross profit margins, and strategic partnerships contribute to a favorable outlook. The absence of negative sentiment in the Q&A session further supports a positive sentiment. Despite a net loss, the reduction in losses and positive EBITDA indicate progress towards profitability, leading to a predicted stock price movement in the 2% to 8% range over the next two weeks.
Key Financial Performance
Revenue $3.9 million for Q2 FY2026, a 19% increase year-over-year from $3.3 million. This growth is attributed to strategic initiatives and technological advancements.
Gross Profit $3.2 million for Q2 FY2026, a 29.4% increase year-over-year from $2.5 million. Gross profit percentage improved to 81.9% from 75.3%, driven by recurring technology fee revenue, AI efficiencies, and cost structure improvements.
Operating Expenses $2.9 million for Q2 FY2026, a 5.1% increase year-over-year from $2.8 million. SG&A expenses rose by 2.5% ($56,000), and R&D expenses increased by $84,000.
EBITDA $373,000 for Q2 FY2026, marking the second consecutive quarter of positive EBITDA. This improvement reflects revenue growth, operating efficiencies, and cost management.
Net Loss $772,000 for Q2 FY2026, a reduction from $1.6 million year-over-year. Loss per share decreased to $0.29 from $0.73, driven by improved operating results and cost-cutting measures.
Operating Highlights
Biocore Pro 2: Next-generation cardiac monitor with expanded capabilities, expected to file for FDA approval by end of Q1 next year.
Biocore Pro: Continued expansion in sales, launch of major cardiac monitoring pilot programs with hospital networks and clinics, accelerating adoption and breakeven path.
AI clinical model and diagnostic technologies: Ongoing development of next-generation diagnostic tools for comprehensive screenings.
Strategic partnerships: Expansion into VA and leading home care groups, as well as pulmonary and neurology partnerships with home-based diagnostic companies.
Geographic footprint: Efforts to expand market penetration through in-sourcing business model and targeting ancillary verticals.
Operational efficiency and automation: Achieved economies of scale with declining operational cost ratios, driving towards a healthy net margin business.
Recurring revenue: Technology-as-a-Service subscription model and usage-based subscriptions driving robust revenue growth.
Cost management: Proactive cost management and AI-driven efficiencies improving gross profit margins and achieving positive free cash flows for five consecutive quarters.
Sales strategy transformation: Focus on longer sales cycles in larger accounts, including independent hospitals and GPO networks, with access to over 90% of U.S. hospitals.
Commercial team expansion: Plans to invest profits into commercial expansion to increase market share and drive top-line growth.
Risk or Challenges
Regulatory Hurdles: The company is in the process of developing a next-generation cardiac monitor (Biocore Pro 2) and plans to file for FDA approval by the end of Q1 next year. Regulatory delays or challenges in obtaining FDA approval could impact the timeline for product launch and revenue generation.
Market Penetration Challenges: While the company has made progress in expanding its market presence, including contracts with VA and home care groups, there is a focus on penetrating larger accounts such as independent hospitals and GPO networks. Longer sales cycles and competition in these markets could pose challenges to achieving desired growth.
Economic Uncertainties: The company’s growth and profitability are tied to market adoption of its products and services. Economic downturns or reduced healthcare spending could adversely affect customer budgets and slow down adoption rates.
Operational Costs and Efficiency: Although the company has achieved economies of scale and positive EBITDA, any unexpected increases in operational costs or inefficiencies in scaling could impact profitability.
Technological Development Risks: The company is heavily reliant on technological advancements, including AI and next-generation diagnostic tools. Delays or failures in technological development could hinder product innovation and competitiveness.
Supply Chain Disruptions: The company’s ability to deliver its products depends on a stable supply chain. Any disruptions could delay product availability and impact customer satisfaction.
Guidance & Outlook
Revenue Growth: The company anticipates further revenue growth in the coming quarters, driven by the sales pipeline and the adoption of its flagship device, Biocore Pro, in hospitals and large clinics.
Profitability: Biotricity is on track to achieve full profitability in the next few quarters, supported by positive free cash flows and consecutive quarters of positive EBITDA.
Product Development: The company plans to file for FDA approval of Biocore Pro 2, its next-generation cardiac monitor, by the end of Q1 next year. Additionally, it is developing a multiparameter cardiac monitor as part of its long-term innovation strategy.
Market Expansion: Biotricity is focused on expanding its commercial team and geographic footprint, including contracts with the VA and leading home care groups. It is also exploring opportunities in ancillary verticals that align with its core business.
Strategic Partnerships: The company is expanding strategic partnerships to build complementary distribution channels and diversify its market reach, including pulmonary and neurology partnerships with home-based diagnostic companies.
Operational Efficiency: Biotricity aims to maintain margins and costs through operational efficiency and automation, achieving economies of scale with declining operational cost ratios for new revenue.
Shareholder Return Plan
Free Cash Flows: Positive free cash flows have been achieved for the last 5 consecutive quarters, defined as the cash from operations available to pay interest and dividends.
Key Q&A
Earnings Word Cloud
BTCY Transcript
The earnings call highlights strong revenue growth, improved profitability, and strategic market expansion. While there are risks, such as regulatory hurdles and market penetration challenges, the company's positive free cash flows, improved gross profit margins, and strategic partnerships contribute to a favorable outlook. The absence of negative sentiment in the Q&A session further supports a positive sentiment. Despite a net loss, the reduction in losses and positive EBITDA indicate progress towards profitability, leading to a predicted stock price movement in the 2% to 8% range over the next two weeks.
The earnings call highlights strong financial performance with a 16.5% YoY revenue increase and a significant improvement in gross margins. Operating expenses have decreased, and there is progress towards profitability with positive adjusted EBITDA in Q4. The Q&A section reveals some uncertainties, but overall, management's optimism and strategic initiatives, like international expansion and data monetization, are positive. Despite some vague timelines, the company's strong financials and strategic plans outweigh the risks, suggesting a positive stock price movement.
The earnings call highlights significant revenue growth, improved gross margins, and reduced operating expenses, indicating strong financial performance. Despite challenges in market expansion and interest rates, the company's strategic initiatives in AI and new market penetration are promising. The Q&A session confirms management's proactive approach to growth and profitability, with no unclear responses. The positive sentiment is reinforced by the company's path to profitability and successful cost management, suggesting a likely stock price increase of 2% to 8% over the next two weeks.
BTCY Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
